Cardiac Hypertrophy: A tail of translational regulation
An RNA-binding protein called PABPC1 has an important role in determining protein synthesis rates and hypertrophy in the heart.
- University of Edinburgh, United Kingdom
The mammalian heart is a muscular pump that handles about five litres of blood per minute in the average human. Muscle cells known as cardiomyocytes make up 25–35% of all cells in the heart, with the remainder largely being vascular endothelial cells and fibroblasts (Pinto et al., 2016). The proliferation of cardiomyocytes is key to the growth of the heart before birth, and also soon after birth, but most cardiomyocytes lose their capacity to proliferate after the early post-natal period in both mice (Soonpaa et al., 1996) and humans (Bergmann et al., 2015). Thereafter, cardiac growth is achieved mainly by increases in the size of cardiomyocytes in a process known as hypertrophy.
In adulthood cardiac hypertrophy can occur as a physiological adaptation to an increased need to pump blood following sustained athletic training or during pregnancy (reviewed in Maillet et al., 2013). Cardiac hypertrophy can also be pathological in nature – for example, when it is caused by long-term hypertension. Although cellular signalling pathways and gene transcription change in distinct ways during 'physiological' and 'pathological' cardiac hypertrophy, both require de novo protein synthesis in order to increase cardiomyocyte size (Figure 1; reviewed in Heineke and Molkentin, 2006). Now, in eLife, Auinash Kalsotra of the University of Illinois and co-workers – including Sandip Chorghade and Joseph Seimetz as joint first authors – reveal an unexpected role for an RNA-binding protein called PABPC1 in cardiac hypertrophy (Chorghade et al., 2017).
Figure 1
The role of the RNA-binding protein PABPC1 in cardiac hypertrophy.
In a normal adult heart, cardiomyocytes (CM) show little growth or turnover, and protein synthesis and PABPC1 levels are low. The temporal overexpression of PABPC1 in adult cardiomyocytes leads to a form of cardiac hypertrophy (top right) that resembles (green arrow) physiological cardiac hypertrophy (e.g. induced by pregnancy or endurance exercise) but not (red broken arrow) pathological cardiac hypertrophy (e.g. induced by long-term hypertension). However, a number of features (such as cardiomyocyte growth, higher protein synthesis and higher levels of PABPC1) are common to both physiological and pathological cardiac hypertrophy. This raises the question (bottom right) of whether PABPC1 function in other types of cardiac cells (such as endothelial cells or fibroblasts) may be important in the induction of pathological cardiac hypertrophy. During cardiac hypertrophy, longer poly(A) tails are associated with more efficient translation of the messenger RNA for PABPC1.
Illustration: Ronnie Grant
PABPC1 (commonly known as PABP1) is one of the 1000+ RNA-binding proteins found in humans, and has multiple functions in controlling the synthesis of new proteins (reviewed in Smith et al., 2014). However, it is best characterized as a factor that is required for efficient messenger RNA (mRNA) translation and to maintain mRNA stability, and it is generally considered to be an abundant and essential protein (Smith et al., 2014).
Protein synthesis is surprisingly low in the adult heart, perhaps reflecting the relatively low level of cell turnover there. Intriguingly, Chorghade et al. show that PABPC1 is abundant in the neonatal heart, but is only present at very low levels in the adult heart, and they go on to show that the low levels of PABPC1 in the adult heart are due to reduced translation of PABPC1 mRNA. Chorghade et al. also found that this reduction in translation coincided with a shortening of the 3’ poly(A) tail of PABPC1 mRNA: poly(A) tails are critical for efficient translation but their length can be exquisitely regulated by a number of mechanisms (reviewed in Charlesworth et al., 2013).
Intriguingly, the length of the poly(A) tail of PABPC1 mRNA and its translation were increased in experimental models of both physiological hypertrophy (induced by swimming) and pathological hypertrophy (induced by narrowing of the aorta to mimic high blood pressure), leading to an increase in PABPC1 levels.
It was already known that the translation of PABPC1 mRNA was controlled by two mechanisms (reviewed in Eliseeva et al., 2013), but uncovering that its poly(A) tail length is also regulated further underscores how important it is to control cellular levels of PABPC1. However, Chorghade et al. found that the 3’untranslated region of PABPC1 mRNA is not important for its regulated translation. This is surprising since studies in multiple cell types have shown that sequences within the 3’untranslated region normally regulate poly(A) tail length. Therefore, more work is needed to clarify the mechanism by which PABPC1 mRNA translation and poly(A) tail length is controlled in cardiomyocytes.
The altered levels of PABPC1 suggested that it may facilitate a dynamic response to an increased workload being placed on the heart. Importantly, Chorghade et al. probed the functional relevance of altered PABPC1 levels and in doing so uncovered new avenues for exploration. Reducing PABPC1 levels in cultured neonatal mouse cardiomyocytes blocked the normal increase in protein synthesis and cell size associated with stimulus-induced growth: moreover, this effect that could be rescued with wild-type PABPC1, but not with mutant PABPC1.
In transgenic mice, the overexpression of PABPC1 in adult cardiomyocytes increased protein synthesis and heart size without any loss of cardiac function, similar to what happens in physiological hypertrophy (Figure 1). The transcriptional changes that accompanied these increases were also similar to physiological rather than pathological hypertrophy. Therefore, despite the level of PABPC1 increasing in models of both forms of hypertrophy, increased PABPC1 levels in cardiomyocytes do not appear sufficient to drive pathological hypertrophy.
Other types of cardiac cells, including endothelial cells and fibroblasts, proliferate during pathological hypertrophy and can influence the behaviour of cardiomyocytes (Figure 1; Frieler and Mortensen, 2015). Future research is needed to determine the extent to which PABPC1 levels in other cardiac cell types may be involved in this process.
In addition to adding to the growing body of evidence that translational control has a role in cardiac hypertrophy, the work of Chorghade et al. also greatly extends our knowledge of the physiological roles of PABPC1. Previous whole-organism studies of PABPC1 function in vertebrates were confined to the frog X. laevis, where it is essential for early embryonic development (Gorgoni et al., 2011).
Since these new results also showed that PABPC1 levels were highest in fetal and neonatal hearts (prior to hypertrophic growth), this suggests that PABPC1 might have a critical role in cell proliferation and/or the growth of heart tissue during heart development and maturation, as well as in adult cardiac hypertrophy. Thus, ascertaining its function in fetal and neonatal hearts in mammals is an exciting question for the future.
Finally, there is significant interest in invoking pathways that promote physiological cardiac hypertrophy as an alternative to the detrimental structural and functional “remodelling” of the heart that is associated with heart failure. The work of Chorghade et al. has opened a new window on our understanding of cardiac hypertrophy, and future research should reveal whether or not PABPC1 has potential as a therapeutic target for cardiovascular disease.
References
-
Specificity factors in cytoplasmic polyadenylationWiley Interdisciplinary Reviews: RNA 4:437–461.https://doi.org/10.1002/wrna.1171
-
Regulation of cardiac hypertrophy by intracellular signalling pathwaysNature Reviews Molecular Cell Biology 7:589–600.https://doi.org/10.1038/nrm1983
-
Molecular basis of physiological heart growth: fundamental concepts and new playersNature Reviews Molecular Cell Biology 14:38–48.https://doi.org/10.1038/nrm3495
-
Revisiting cardiac cellular compositionCirculation Research 118:400–409.https://doi.org/10.1161/CIRCRESAHA.115.307778
-
Poly(A)-binding proteins are required for diverse biological processes in metazoansBiochemical Society Transactions 42:1229–1237.https://doi.org/10.1042/BST20140111
-
Cardiomyocyte DNA synthesis and binucleation during murine developmentAmerican Journal of Physiology 271:H2183–H2189.
Article and author information
Author details
Publication history
- Version of Record published: June 27, 2017 (version 1)
Copyright
© 2017, Gray et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,725
- views
-
- 292
- downloads
-
- 5
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Cardiac Hypertrophy: A tail of translational regulation
eLife 6:e29104.
https://doi.org/10.7554/eLife.29104
Further reading
-
- Biochemistry and Chemical Biology
- Plant Biology
Transmembrane signaling by plant receptor kinases (RKs) has long been thought to involve reciprocal trans-phosphorylation of their intracellular kinase domains. The fact that many of these are pseudokinase domains, however, suggests that additional mechanisms must govern RK signaling activation. Non-catalytic signaling mechanisms of protein kinase domains have been described in metazoans, but information is scarce for plants. Recently, a non-catalytic function was reported for the leucine-rich repeat (LRR)-RK subfamily XIIa member EFR (elongation factor Tu receptor) and phosphorylation-dependent conformational changes were proposed to regulate signaling of RKs with non-RD kinase domains. Here, using EFR as a model, we describe a non-catalytic activation mechanism for LRR-RKs with non-RD kinase domains. EFR is an active kinase, but a kinase-dead variant retains the ability to enhance catalytic activity of its co-receptor kinase BAK1/SERK3 (brassinosteroid insensitive 1-associated kinase 1/somatic embryogenesis receptor kinase 3). Applying hydrogen-deuterium exchange mass spectrometry (HDX-MS) analysis and designing homology-based intragenic suppressor mutations, we provide evidence that the EFR kinase domain must adopt its active conformation in order to activate BAK1 allosterically, likely by supporting αC-helix positioning in BAK1. Our results suggest a conformational toggle model for signaling, in which BAK1 first phosphorylates EFR in the activation loop to stabilize its active conformation, allowing EFR in turn to allosterically activate BAK1.
-
- Biochemistry and Chemical Biology
- Neuroscience
Amyloid β (Aβ) peptides accumulating in the brain are proposed to trigger Alzheimer’s disease (AD). However, molecular cascades underlying their toxicity are poorly defined. Here, we explored a novel hypothesis for Aβ42 toxicity that arises from its proven affinity for γ-secretases. We hypothesized that the reported increases in Aβ42, particularly in the endolysosomal compartment, promote the establishment of a product feedback inhibitory mechanism on γ-secretases, and thereby impair downstream signaling events. We conducted kinetic analyses of γ-secretase activity in cell-free systems in the presence of Aβ, as well as cell-based and ex vivo assays in neuronal cell lines, neurons, and brain synaptosomes to assess the impact of Aβ on γ-secretases. We show that human Aβ42 peptides, but neither murine Aβ42 nor human Aβ17–42 (p3), inhibit γ-secretases and trigger accumulation of unprocessed substrates in neurons, including C-terminal fragments (CTFs) of APP, p75, and pan-cadherin. Moreover, Aβ42 treatment dysregulated cellular homeostasis, as shown by the induction of p75-dependent neuronal death in two distinct cellular systems. Our findings raise the possibility that pathological elevations in Aβ42 contribute to cellular toxicity via the γ-secretase inhibition, and provide a novel conceptual framework to address Aβ toxicity in the context of γ-secretase-dependent homeostatic signaling.
